New hope for schizophrenia: drug aims to stop relapses
NCT ID NCT07227818
First seen Nov 13, 2025 · Last updated May 14, 2026 · Updated 24 times
Summary
This study tests whether the drug NBI-1117568 can delay or prevent the return of schizophrenia symptoms in adults who have already responded well to the drug. About 560 participants will first receive the drug openly, then be randomly assigned to continue the drug or switch to a placebo. The main goal is to see how long it takes for symptoms to return.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Neurocrine Clinical Site
RECRUITINGGarden Grove, California, 92845, United States
-
Neurocrine Clinical Site
RECRUITINGLa Habra, California, 90631, United States
-
Neurocrine Clinical Site
RECRUITINGLemon Grove, California, 91945, United States
-
Neurocrine Clinical Site
RECRUITINGOceanside, California, 92056, United States
-
Neurocrine Clinical Site
RECRUITINGWest Hills, California, 91307, United States
-
Neurocrine Clinical Site
RECRUITINGHollywood, Florida, 33024, United States
-
Neurocrine Clinical Site
RECRUITINGMaitland, Florida, 32751, United States
-
Neurocrine Clinical Site
RECRUITINGMiami, Florida, 33122, United States
-
Neurocrine Clinical Site
RECRUITINGTampa, Florida, 33629, United States
-
Neurocrine Clinical Site
RECRUITINGWest Palm Beach, Florida, 33024, United States
-
Neurocrine Clinical Site
RECRUITINGAtlanta, Georgia, 30318, United States
-
Neurocrine Clinical Site
RECRUITINGBoston, Massachusetts, 02116, United States
-
Neurocrine Clinical Site
RECRUITINGFlowood, Mississippi, 39232, United States
-
Neurocrine Clinical Site
RECRUITINGCedarhurst, New York, 11516, United States
-
Neurocrine Clinical Site
RECRUITINGNew York, New York, 10029, United States
-
Neurocrine Clinical Site
RECRUITINGNew York, New York, 10036, United States
-
Neurocrine Clinical Site
RECRUITINGBellevue, Washington, 98007, United States
Conditions
Explore the condition pages connected to this study.